theory clinical_64_5
imports Main

begin

typedecl entity
typedecl event

consts
  KinaseInhibitor :: "entity ⇒ bool"
  Mutations :: "entity ⇒ bool"
  PI3KAKTPathway :: "entity ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Survival :: "entity ⇒ bool"
  Target :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Treatment :: "entity ⇒ bool"
  AlpelisibFulvestrant :: "entity ⇒ bool"
  PIK3CAMutation :: "entity ⇒ bool"
  Patients :: "entity ⇒ bool"
  PIK3CAMutated :: "entity ⇒ bool"
  HRPositive :: "entity ⇒ bool"
  HER2Negative :: "entity ⇒ bool"
  AdvancedBreastCancer :: "entity ⇒ bool"
  EndocrineTherapy :: "entity ⇒ bool"
  Directly :: "event ⇒ bool"
  Beneficial :: "event ⇒ bool"
  For :: "event ⇒ entity ⇒ bool"
  Received :: "event ⇒ bool"
  Previously :: "event ⇒ bool"
  Prolongs :: "event ⇒ bool"
  ProgressionFreeSurvival :: "event ⇒ bool"
  Benefit :: "event ⇒ bool"
  From :: "event ⇒ entity ⇒ bool"
  PatientEntity :: "entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  LikelyLessSensitiveTo :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. KinaseInhibitor x ∧ Mutations y ∧ PI3KAKTPathway y ∧ Proliferation z ∧ Survival z ∧ (Target e1 ∧ Agent e1 x ∧ Patient e1 y) ∧ (Inhibit e2 ∧ Agent e2 x ∧ Patient e2 z)"

(* Explanation 2: Treatment with alpelisib–fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)
axiomatization where
  explanation_2: "∃x y z w e1 e2 e3. Treatment x ∧ AlpelisibFulvestrant x ∧ PIK3CAMutation y ∧ Patients z ∧ PIK3CAMutated z ∧ HRPositive z ∧ HER2Negative z ∧ AdvancedBreastCancer z ∧ EndocrineTherapy w ∧ (Target e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Directly e1) ∧ (Beneficial e2 ∧ For e2 z ∧ Received e3 ∧ Agent e3 z ∧ Patient e3 w ∧ Previously e3) ∧ (Prolongs e2 ∧ Agent e2 x ∧ ProgressionFreeSurvival e2)"

(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant. *)
axiomatization where
  explanation_3: "∃x y z w e1 e2. Patients x ∧ EndocrineTherapy y ∧ PIK3CAMutated x ∧ HRPositive x ∧ HER2Negative x ∧ AdvancedBreastCancer x ∧ Treatment z ∧ AlpelisibFulvestrant z ∧ (Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1) ∧ (Benefit e2 ∧ Agent e2 x ∧ From e2 z)"

(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)
axiomatization where
  explanation_4: "∀x y. PatientEntity x ∧ Chemotherapy y ⟶ LikelyLessSensitiveTo x y"

theorem hypothesis:
  assumes asm: "PatientEntity x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1"
  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)
  shows "∀x y z e1 e2. (PatientEntity x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1) ⟶ (Benefit e2 ∧ Agent e2 x ∧ Treatment z ∧ From e2 z ∧ AlpelisibFulvestrant z ∧ (∃v. Target e2 ∧ PIK3CAMutation v))"
proof -
  (* From the premise, we have information about the patient entity and their previous endocrine therapy. *)
  from asm have "PatientEntity x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Previously e1" by blast
  (* Explanation 3 provides a logical relation Implies(H, I), which states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)
  (* We can use this to infer that the patient may benefit from the treatment. *)
  then have "Benefit e2 ∧ Agent e2 x ∧ From e2 z ∧ Treatment z ∧ AlpelisibFulvestrant z" sledgehammer
  (* Explanation 2 states that treatment with alpelisib–fulvestrant directly targets the PIK3CA mutation. *)
  (* Therefore, we can conclude that there exists a PIK3CA mutation targeted by the treatment. *)
  then have "∃v. Target e2 ∧ PIK3CAMutation v" <ATP>
  then show ?thesis <ATP>
qed

end
